NCT00635154 - Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

December 31, 2009

Study Completion Date

November 30, 2010

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

BIOLOGICAL

Anakinra (IL-1Ra)

100mg daily subcutaneously administered

DRUG

Dexamethasone acetate

"Low dose - 20 mg/week~High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)"

Trial Locations (1)

55905

Mayo Clinic, Rochester